Summary The selective BCR-ABL tyrosine kinase inhibitor imatinib is amongst the first-line therapies while in the administration of chronic myeloid leukaemia (CML). However, acquired resistance to this inhibitor, which is very conferred by the T315I issue mutation in BCR-ABL, impedes the efficacy of imatinib therapy. Consequently, the invention and advancement https://wardi296uyd9.therainblog.com/profile